Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 8/20 | 0.57 |
| ▸ | NAALAD2 | Q9Y3Q0 | 3/20 | 0.57 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.57 |
| ▸ | GGH | Q92820 | 1/20 | 0.48 |
| ▸ | TET2 | Q6N021 | 3/20 | 0.43 |
| ▸ | KDM4A | O75164 | 2/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.43 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.43 |
| ▸ | TET3 | O43151 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | GRM8 | O00222 | 1/20 | 0.41 |
| ▸ | GRM6 | O15303 | 1/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | GSR | P00390 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.41 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL702004 | 1.00 | FOLH1 (0.57) | FOLH1NAALAD2RIMKLAGGHTET2 | |
| SCHEMBL15935963 | 1.00 | FOLH1 (0.57) | FOLH1NAALAD2RIMKLAGGHTET2 | |
| SCHEMBL28883926 | 0.98 | FOLH1 (0.55) | FOLH1NAALAD2RIMKLAGGHTET2 | |
| SCHEMBL10699563 | 0.86 | FOLH1 (0.45) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL18583123 | 0.84 | LMNA (0.44) | FOLH1NAALAD2RIMKLA | |
| Aniline SCHEMBL27955361 | 0.83 | NAALAD2 (0.48) | FOLH1NAALAD2RIMKLAGGH | |
| Aniline SCHEMBL27955360 | 0.83 | NAALAD2 (0.48) | FOLH1NAALAD2RIMKLAGGH | |
| SCHEMBL7046561 | 0.83 | KMT2A (0.47) | FOLH1NAALAD2RIMKLAGGH | |
| SCHEMBL2920459 | 0.83 | KMT2A (0.47) | FOLH1NAALAD2RIMKLAGGH | |
| SCHEMBL2923058 | 0.83 | FOLH1 (0.44) | FOLH1NAALAD2RIMKLAGGHTET2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116267786-A | Method for improving summer synchronous estrus-timing insemination effect of buffalo | 安徽科技学院 | 2023-06-23 | — | — | CN | claimed |
| CN-110368132-B | Treatment method for improving synchronous estrus-timing insemination effect of dairy cows in summer | 华中农业大学 | 2020-09-15 | — | — | CN | claimed |
| US-4725582-A | IMMUNE RESPONSE ENHANCERS | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1988-02-16 | — | — | US | claimed |
| US-20250268855-A1 | PHARMACEUTICAL AND NUTRACEUTICAL COMPOSITIONS WITH A COMBINATION OF AMINO ACIDS AND ITS USE IN DISEASES CHARACTERIZED BY LIPID ACCUMULATION IN TISSUES | FUNDACIÓ EURECAT (ES) | 2025-08-28 | — | — | US | disclosed |
| EP-4514147-A1 | PHARMACEUTICAL AND NUTRACEUTICAL COMPOSITIONS WITH A COMBINATION OF AMINO ACIDS AND ITS USE IN DISEASES CHARACTERIZED BY LIPID ACCUMULATION IN TISSUES | Fundació Eurecat (ES) | 2025-03-05 | — | — | EP | disclosed |
| CN-119343061-A | Pharmaceutical and nutraceutical compositions containing amino acid combinations and their use in diseases characterized by lipid accumulation in tissues | 欧罗卡特基金会 | 2025-01-21 | — | — | CN | disclosed |
| CN-117625530-A | Modified memory T cell based on metabolic regulation and modification method thereof | 华中科技大学 | 2024-03-01 | — | — | CN | disclosed |
| CN-117191963-A | Biomarkers, systems, and uses thereof for predicting whether progression to ACLF or mortality in ACLF patients will occur | 上海甘宁医疗科技有限公司 | 2023-12-08 | — | — | CN | disclosed |
| WO-2023208944-A1 | PHARMACEUTICAL AND NUTRACEUTICAL COMPOSITIONS WITH A COMBINATION OF AMINO ACIDS AND ITS USE IN DISEASES CHARACTERIZED BY LIPID ACCUMULATION IN TISSUES | FUNDACIÓ EURECAT (ES) | 2023-11-02 | — | — | WO | disclosed |
| CN-116267786-A | Method for improving summer synchronous estrus-timing insemination effect of buffalo | 安徽科技学院 | 2023-06-23 | — | — | CN | disclosed |
| CN-116267786-A | Method for improving summer synchronous estrus-timing insemination effect of buffalo | 安徽科技学院 | 2023-06-23 | — | — | CN | disclosed |
| US-20040171836-A1 | Method for producing optical-active cis-piperidine derivatives | TORAY FINE CHEMICALS CO., LTD., A CORPORATION OF JAPAN, (JP) | 2004-09-02 | — | — | US | disclosed |
| EP-1412349-A2 | PIPERAZINE OXYQUINOLINE (NAPHTHALINE) PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS | Schering Aktiengesellschaft (DE) | 2004-04-28 | — | — | EP | disclosed |
| US-20030060474-A1 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-03-27 | — | — | US | disclosed |
| WO-2002098856-A2 | PIPERAZINE OXYQUINOLINE (NAPHTHALINE) PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-12-12 | — | — | WO | disclosed |
| US-5952503-A | Method for producing optically-active 2-piperazinecarboxylic acid derivatives | TORAY INDUSTRIES, INC. (JP) | 1999-09-14 | — | — | US | disclosed |
| EP-0906906-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE 2-PIPERAZINECARBOXYLIC ACID DERIVATIVES | TORAY INDUSTRIES, INC. (JP) | 1999-04-07 | — | — | EP | disclosed |
| US-5763437-A | Benzodiazepine derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-06-09 | — | — | US | disclosed |
| EP-0388456-A1 | 8,10-DIDEAZATETRAHYDROFOLIC ACID DERIVATIVES | SRI INTERNATIONAL (US) | 1990-09-26 | — | — | EP | disclosed |
| WO-1990002745-A1 | 8,10-DIDEAZATETRAHYDROFOLIC ACID DERIVATIVES | SRI INTERNATIONAL (US) | 1990-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171836-A1 | Method for producing optical-active cis-piperidine derivatives | TYR, DDC, TARBP1 | FOLH1 551/4885NAALAD2 62/4885RIMKLA 709/4885 |
| US-20030060474-A1 | Platelet adenosine diphosphate receptor antagonists | ADORA1, TBXA2R, ADORA2B | FOLH1 3130/4885NAALAD2 2084/4885RIMKLA 1928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.